Isomorphic Labs raises $5bn in massive third round

News
Sir Demis Hassabis
Isomorphic Labs

Sir Demis Hassabis.

In yet another sign of the insatiable appetite for AI companies among investors, Isomorphic Labs has raised $5 billion in Series C financing, just months after claiming $2.1 billion in a second round.

Greenoaks and Sequoia Capital led the latest financing for the London, UK start-up, which was set up as a spinout from Google DeepMind in 2021 and is led by DeepMind founder Sir Demis Hassabis. It takes the total raised by Isomorphic since then to more than $7.7 billion and has swelled its paper value to an estimated $50 billion.

Other investors in the round included Andreessen Horowitz and Google's parent Alphabet, along with existing backers Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.

The increasing scale of the investments adds to the sense of building momentum at Isomorphic, even though it has yet to move any drug candidates into clinical trials, and comes after a string of big-ticket research partnerships with pharma groups, including Johnson & Johnson, Novartis, and Eli Lilly.

In a statement, Isomorphic said it would use the funding to build and refine its foundational simulation models, progress and scale its internal and partnered medicine candidate pipeline, and build its global AI-led bioengineering infrastructure.

Its platform is built around IsoDDE, a drug design engine constructed around a suite of foundational simulation AI models that can be used to predict 3D protein structures and their interactions with drug candidates, including small molecules, model binding affinities, and discover new binding 'pockets'.

The platform is "yielding positive preclinical results, both for internal programmes in oncology and immunology and with partners, setting the stage for clinical entry," according to Isomorphic.

"Our drug design engine is generating molecules with unprecedented precision and speed," said Hassabis.

"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programmes towards clinical trials to deliver tangible impact for patients."

The size of the Series C is also a fillip for the UK biotech sector, and puts 2026 firmly on track to be a banner year for venture financing, albeit with Isomorphic commanding the bulk of the total.